Search results
Results from the WOW.Com Content Network
The duration of antithrombotic therapy for ATE is variable, depending on the type and location of the thrombus, the presence of a prosthetic device, and the bleeding risk. In general, patients with ATE receive lifelong antiplatelet therapy unless there is a specific indication or contraindication for anticoagulation. [2] [10]
There are no comparative trials to determine the best course of action for renal infarction brought on by thromboemboli, in situ thrombosis, or renal artery dissection. Reported treatments include open surgery, endovascular therapy, endovascular therapy ( thrombolysis / thrombectomy with or without angioplasty ), and anticoagulation.
Pump thrombosis is defined as a specific case of a major device malfunction. In turn, device malfunction is as defined by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) as a failure of one or more of the components of the mechanical circulatory support systems which either directly causes or could potentially induce a state of inadequate circulatory support (low ...
Direct Xa inhibitor, novel oral anticoagulant: Use: Treat and prevent venous thromboembolism: Mechanism of action: Inhibit fibrin formation in the final common pathway of the coagulation cascade: Chemical class: Direct factor Xa inhibitors [1] Legal status; In Wikidata
If the patient is 'low risk' using the CHA 2 DS 2-VASc score (that is, 0 in males or 1 in females), no anticoagulant therapy is recommended. In males with 1 stroke risk factor (that is, a CHA 2 DS 2 -VASc score=1), antithrombotic therapy with OAC may be considered, and people's values and preferences should be considered. [ 24 ]
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation. [1] Development was stopped by manufacturer AstraZeneca , however, because of reports of liver enzyme derangements and liver failure .
A thrombus (pl. thrombi), colloquially called a blood clot, is the final product of the blood coagulation step in hemostasis. There are two components to a thrombus: aggregated platelets and red blood cells that form a plug, and a mesh of cross-linked fibrin protein. The substance making up a thrombus is sometimes called cruor.